These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7747720)

  • 1. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited.
    Llach F
    Am J Kidney Dis; 1995 May; 25(5):663-79. PubMed ID: 7747720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects.
    Llach F; Velasquez Forero F
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S20-33. PubMed ID: 11689384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy.
    Rodriguez M; Felsenfeld AJ; Llach F
    Kidney Int; 1991 Dec; 40(6):1063-8. PubMed ID: 1762307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol.
    Rodriguez M; Martin-Malo A; Martinez ME; Torres A; Felsenfeld AJ; Llach F
    Kidney Int; 1991 Dec; 40(6):1055-62. PubMed ID: 1762306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E; Delmez JA
    Am J Kidney Dis; 1994 Feb; 23(2):229-36. PubMed ID: 8311080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
    Morio K; Koide K
    Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure.
    Slatopolsky E; Dusso A; Brown AJ
    Am J Med Sci; 1999 Jun; 317(6):370-6. PubMed ID: 10372836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure.
    Sawaya BP; Koszewski NJ; Qi Q; Langub MC; Monier-Faugere MC; Malluche HH
    J Am Soc Nephrol; 1997 Feb; 8(2):271-8. PubMed ID: 9048346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology and treatment of secondary hyperparathyroidism in patients with chronic renal failure.
    Tsukamoto Y
    Nephrol Dial Transplant; 1995; 10 Suppl 3():22-4. PubMed ID: 7494609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism.
    Martinez I; Saracho R; Montenegro J; Llach F
    Nephrol Dial Transplant; 1996; 11 Suppl 3():22-8. PubMed ID: 8840307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Peculiar problems of phosphocalcium metabolism in chronic renal insufficiency].
    Drüeke T
    Rev Prat; 1989 Apr; 39(11):954-8. PubMed ID: 2717868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
    Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
    J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
    Slatopolsky E; Finch J; Ritter C; Takahashi F
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
    Brancaccio D; Cozzolino M; Galassi A; Bellasi A; Carpani P; Gallieni M
    G Ital Nefrol; 2003; 20 Suppl 22():S12-6. PubMed ID: 12851915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Apoptosis in parathyroid of uremic patients with secondary hyperparathyroidism and the influence of Ca2+ and calcitriol on APO].
    Zhang P; Wei J; Han D
    Zhonghua Nei Ke Za Zhi; 1999 Mar; 38(3):161-3. PubMed ID: 11798642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone growth during daily or intermittent calcitriol treatment during renal failure with advanced secondary hyperparathyroidism.
    Sanchez CP; He YZ
    Kidney Int; 2007 Sep; 72(5):582-91. PubMed ID: 17554252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure.
    Korkor AB
    N Engl J Med; 1987 Jun; 316(25):1573-7. PubMed ID: 3035373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.